Compare Macy's Inc (M) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Smith & Nephew plc — how do they compare? Macy's Inc trades at $22.67 (market cap $5.95B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Smith & Nephew plc for 121 Days on average.
| M | SNN | |
|---|---|---|
Market Cap | $5.95B | $11.10B |
Volume | 6,030,644 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $37.17 |
52-Week Low | $16.51 | $26.42 |
Typical Hold Time | 58 Days | 121 Days |
Enterprise Value | $9.75B | $14.13B |
Dividend Yield | 3.36% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, indicating potential undervaluation. The stock shows bullish technical signals with recent earnings beats in Q2 2026 and raised 2026 guidance. Cash flow improved to $273M in 2025, while revenue stabilized at $23.01B with net income of $582M. The company's 'Bold New Chapter' strategy is driving digital transformation and omnichannel growth.
Investment outlook appears favorable with 31.7% analyst buy ratings and $24.25 consensus price target suggesting 6.4% upside. Key risks include retail sector competition and uneven quarterly performance, but strong dividend yield and turnaround progress support total return potential for patient investors.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
